Becker's Spine Review

DEVICES & IMPLANTS 25 Who is Mazor Robotics' Biggest Competitor in the Spine Market? By Mackenzie Garrity W ith FDA approval of its Ex- celsius GPS in place, Globus Medical set itself up to stand as Mazor Robotics biggest rival in the spine market, according to e Motley Fool. Here's what you need to know. 1. Mazor Robotics currently has more than 170 surgical robotic systems installed across the world and an additional 22 sys- tems orders in the third quarter of 2017. 2. Globus Medical received FDA clearance for the Excelsius GPS robotic guidance and navigation system in August aer facing various setbacks. e company originally planned to launch the minimally invasive system in 2016. 3. While recently entering the robotics market, Globus Medical has a strong pres- ence in the spinal surgery market. Last year, the spine device company acquired Al- phatec. Globus Medical has also seen pos- itive interest from hospitals and physicians regarding the Excelsius GPS. 4. Mazor Robotics continues to make strides with its relationship with Medtron- ic. As the two advance to the next phase of their partnership, Medtronic is looking to assume worldwide distribution of the Ma- zor X system. is phase of the partnership included a third investment of $40 million in Mazor Robotics. 5. Intuitive Surgical is another Mazor com- petitor. While the company has not official- ly entered into the spine market, Intuitive Surgical is pioneering robotics. Addition- ally, Zimmer Biomet's recent acquistion of Medtech adds more competition. n 8 Orthopedic, Spine Device Companies Who Spent the Most on Non-Research Payments to Florida Physicians — Zimmer Biomet Leads With $4.473M By Mackenzie Garrity H ere are eight orthopedic and spine device companies who spend the most on non-research payments to Florida physicians, according to the Orlando Business Journal. 1. Zimmer Biomet — $4,473,263 2. Intuitive Surgical — $4,074,469 3. Stryker — $3,986,854 4. Smith & Nephew — $3,321,919 5. Medtronic — $3,166,438 6. DePuy Synthes — $3,005,904 7. Nuvasive — $2,504,982 8. Exactech — $1,484,579 n J&J Reports Declining Spine Sales in Q3 – What to Expect in Q4 By Mackenzie Garrity A lthough reporting $19.7 billion total sales in the third quarter of 2017, Johnson & Johnson's spine division saw a decline in sales, according to Market Realist. Here's what you need to know. 1. With the emergence of competitors, such as Medtronic, Zimmer Biomet and Stryker, Johnson and Johnson's spine sales and market share have continued to decline in the U.S. 2. Gaps in Johnson & Johnson's spine portfolio have also influenced declines in sales. However, the company claimed internal and macroeconomic factors as reasons for weak sales. 3. While the device company estimates the U.S. and North American spine mar- kets are experiencing lower procedure volumes, Johnson & Johnson's spine sales were positive in Asian and Latin American markets. 4. In the upcoming quarter, Johnson & Johnson plans to launch devices from its recent acquisitions. Johnson & Johnson acquired Sentio, a company that mar- kets spine surgery technology, in June 2017. 5. To fill the gaps in its spine portfolio, Johnson & Johnson also acquired Inter- ventional Spine Expandable Cage Technology, and in late October the compa- ny's DePuy Synthes subsidiary launched its Viper Prime System and Concorde Clear MIS Discectomy Tool. n

• Cover